We are an IND-stage drug discovery and development platform advancing transformative new medicines. Our proprietary R2i technology delivers novel therapeutics that overcome the side effect profiles and limited efficacy of traditional pharmacological approaches by leveraging a new dimension of disease biology. Blue’s proprietary receptor-interactomics™ approach is creating deep insights to deliver superior outcomes for patients.